Short Interest & Thesis

Bottom Line

No deterministic official short-interest, public net-short, or borrow-pressure data is staged for 3099.T in this run, so the headline question — "is the name crowded short?" — cannot be answered from staged feeds. What the primary record does show is a setup that runs in the opposite direction of a typical short thesis: management is aggressively shrinking the share count via repeated buybacks and treasury-share cancellation, has raised the total payout ratio to ≥70% on a record-profit base, and frames its capital-allocation pivot as a deliberate response to a rising equity cost of capital and high single-name volatility — not to short-seller pressure. The only positioning signal that survives a clean read of the corpus is that mid-2024 saw a sharp price-and-volume shock (a 46% drawdown from peak to 5-Aug-2024 close on multi-day forced-flow tape), and management itself flagged elevated CAPM-implied equity cost as the active concern.

Evidence gap (read this first). The short-interest data layer for this market is unsupported in the v1 pipeline. Reported short interest, short-sale-volume, borrow fees, utilization, and public net-short disclosures are all empty in data/short_interest/. Everything below is built from the primary filings, transcripts, and the price tape — not from a TSE margin-trading feed.

Source Reality: What Is and Is Not Decision-Useful

No Results

Concretely: data/short_interest/latest.json returns "status": "unavailable", and the source manifest classifies the official channel as unsupported_market. The TSE does publish margin-trading data (信用買残/売残) on a name-by-name basis, which is the cleanest Japanese analog to U.S. reported short interest, but no row was staged in this run — so any "Isetan Mitsukoshi is/isn't crowded" claim against that feed is unsupported by the corpus and is not made on this page.

What the Primary Record Tells Us Instead

Even without a short-interest feed, the corpus answers the institutional question — does positioning or a credible short thesis change the case? — in a specific direction. Management is operating like a name whose investor base it is trying to lengthen, not defend.

Issued shares fell from 397,265,054 at 31-Mar-2024 [1] to 380,262,554 at 31-Mar-2025 [2] and to 367,446,554 at 31-Mar-2026 [3], with the yuho's five-year share-count table making the cancellation cadence explicit [4]. That is roughly 29.8 million shares retired in two years, ~7.5% of the FY2024 base.

Treasury holdings rose from 14,852,729 at 31-Mar-2025 [2] to 16,712,323 at 31-Mar-2026 as the company bought back ¥12.97 billion of stock during the year while cancelling 12,867,100 shares, per the yuho's treasury-movement schedule [5]. On 6-Feb-2026 the board authorized an additional equity buyback of up to 18,000,000 shares, representing 5.12% of the share base for ¥30 billion (¥30,000 million), with treasury shares to be cancelled, per the company announcement [6]. On the Q3 FY2026 web briefing, management framed the ¥30bn (¥300億円) authorization as the natural use of "earnings upside plus cash inflow from related-party stock sales," sized inside a three-year Phase 1 total-shareholder-return commitment of ¥150bn (¥1,500億円) at a 70% total payout ratio [7]. This is the wrong tape for a short thesis built on dilution, balance-sheet stress, or shareholder neglect.

2. The register is dominated by passive trustees and long-term Japanese holders, with foreign ownership ~17-18%

At 31-Mar-2025 the top of the register was the two domestic trust banks (Master Trust 16.72%, Custody Bank 8.33%), the company-affiliated Mitsukoshi Welfare Foundation 3.61%, JPMorgan Chase 385864 2.68%, and the group's business-partner shareholding club 1.98%, with total shareholder count of 315,582 and 14,852,729 treasury shares (3.91% of issued) carved out of the ratio denominator [2]. One year earlier at 31-Mar-2024 the same trust banks held 17.76% and 9.26%, foreign ownership stood at 17.40%, and treasury was 21,927,440 shares or 5.52% of issued [1]. The buyback program is doing exactly what management says it is doing: pulling the treasury share line down and pushing the per-share-economics line up, while foreign ownership ticked up from 17.40% to 17.81%.

Note the structural implication: the two trust banks (Master Trust 16.72% + Custody Bank 8.33% at FY25) are nominee accounts that typically settle index, pension, and lending-related positions — not directional longs. Even so, the active-directional free float is what would have to be borrowed for a short, and the heavy passive overlay does not make the borrow particularly deep.

3. The cost-of-capital concern is the company's own, and it is volatility-driven, not allegation-driven

Management devoted a full page of the FY2025 integrated report to "stock price trend and cost-of-capital recognition," noting the share price doubled from below ¥1,000 to the ¥2,000s over FY2022–FY2024 and that PBR has held above 1× since FY2022 — and then explicitly conceded that since 2024 single-name volatility has risen and the CAPM-implied equity cost of capital with it, framing the response as "lengthen the investor base, deepen IR dialogue, and continue cross-shareholding reduction" rather than as a market-microstructure problem [8]. On the supporting chart, single-name historical volatility spiked to roughly 75% around mid-2024 versus TOPIX at roughly 38%, and the gap (~41 percentage points) is what management is targeting [8]. Importantly, no transcript surfaces a question about short-seller pressure, accounting allegations, or activist short positioning — Q-and-A is consistently about luxury MD mix, inbound, store renovation, and capital-return cadence [9] [10].

4. Liquidity is decent for a TSE Prime mid-cap; the actionable risk is gap risk on macro shocks, not crowding

252-day ADV (shares)

2,310,538

252-day ADV (¥B turnover)

6.18

Last close (¥)

3,871

Non-treasury shares (thousands, Mar-2026)

350,734

ADV is calculated from the staged daily price file (2,464 trading days through 19-Jun-2026); recent 30-day, 90-day, and 252-day average daily volumes are 2.29m, 2.10m, and 2.31m shares respectively, equating to roughly ¥6.2bn of turnover at the current ¥3,871 close. Non-treasury shares ≈ 367.4m issued less 16.7m treasury = ~350.7m at 31-Mar-2026 [3] [5]. The tape shows what real positioning stress looks like for this name: the four largest non-COVID volume days clustered between May and October 2024, with the 5-Aug-2024 close at ¥1,965 representing a 46% drawdown from the 11-Jul-2024 intraday peak of ¥3,624 — coincident with the BOJ-rate-hike volatility wave and management's mid-2024 volatility spike. This is gap risk on macro shocks, not the signature of a sustained short squeeze.

The shape — a tight cluster of forced-flow days through 2024's volatility regime, then normalization back to ~2-3m ADV — is consistent with a Japan-wide de-risking unwind, not with a name-specific crowded-short setup that would typically leave a persistent volume floor.

5. The risk-factor disclosure is generic and lacks the language a short thesis usually needs

The FY2024 integrated report frames group risk in five buckets — strategic, financial, HR/labor, disaster, operational — with the financial bucket listing only "fundraising, market interest-rate increase, FX fluctuation" and the operational bucket covering "merchandise transaction risk, food-hygiene incidents, personal-information leakage" [11]. The FY2025 integrated report repeats the three-line-of-defense / five-layer framework and adds a cyber-security committee, with no specific going-concern, covenant, related-party, revenue-recognition, or litigation-disclosure language that a short report would typically anchor on [12]. The financial highlights show four consecutive years of operating-profit growth, FY2024 PBR back above 1×, ROE 8.8% and ROIC 7.6% with management explicitly targeting 10% ROE [13]. That is the opposite of the disclosure profile that supports a credible short thesis.

Short-Thesis Ledger

For completeness, the ledger below catalogs the only short-thesis-adjacent talking points that are visible in the staged record and the company-side rebuttal anchored in the primary filings. None rise to the level of a credible, actionable short thesis.

No Results

The China-exposure stress-test is paraphrased from the Q3 FY2026 web briefing, where the CFO sized inbound at ~11% of consolidated sales, China+HK ~50% of that, and concluded a 30% China decline implied ~2% of annual revenue at risk [7]. The "tighten shareholder focus / DOE-based policy / total payout ≥70%" stance was first publicly framed on the Q3 FY2024 call when management said the total-payout-ratio target was 50% [10] and was raised to 70% by the Q3 FY2026 call [7].

Market Setup and Catalyst Read-Across

The 6-Feb-2026 ¥30bn / 18.0m-share / 5.12%-of-float buyback running through Feb-2027 [6] acts as a standing bid of roughly ¥1,667 per share on average if fully executed at ratio. Sized against a 252-day ADV of ~2.31m shares, the program represents roughly 7.8 trading days of cumulative volume — non-trivial near-term demand at this float.
The cancellation cadence (29.8m shares retired across FY2024–FY2026) is not a one-off — it is a 3-year pattern that re-prices any short on a per-share-economics basis even if the absolute share-price path is unchanged.
Earnings-day volume clusters (Aug 9, Nov 13, Feb 6, May 13 each year) are the cleanest gap-risk windows; the largest single-day volumes outside earnings days clustered around the BOJ-rate-shock period of Aug-Oct 2024, which suggests macro/forced-de-risking is the dominant tape risk, not name-specific positioning.
There is no public short-seller report, no activist short campaign, and no accounting/forensic allegation in the staged record. The asymmetric "thesis risk" channel on this name is therefore macro (Japan rate regime, China inbound) rather than narrative (short-report-driven).

Evidence Limitations

No Results

For an institutional read, the honest answer is: short interest as a positioning signal cannot be produced here. The corpus instead supports a thesis-risk read — and on that read, the setup looks short-unfriendly: shrinking share count, rising payout, no allegation-based narrative, with the active risk being macro-tape volatility (which the company itself has flagged and is explicitly trying to compress through capital allocation and IR).

References

Generated Jun 19, 2026 18:29 UTC